Takeda quiet on possible $2bn+ Actos settlement

Despite a report that it may be considering settling thousands of US lawsuits relating to its former blockbuster diabetes drug Actos, Takeda Pharmaceutical has so far given no indications it intends to do so.

Despite a report that it may be considering settling thousands of US lawsuits relating to its former blockbuster diabetes drug Actos, Takeda Pharmaceutical has so far given no indications it intends to do so.

While a media report earlier this month suggested that Takeda has already offered to pay a total of $2.2bn to...

More from Alimentary/Metabolic

More from Therapy Areas

BMS’s Reblozyl Misses Primary Endpoint In Myelofibrosis Anemia

 

The drugmaker announced topline results from the Phase III INDEPENDENCE trial, which did meet key secondary endpoints.

Insmed’s New R&D Site Focused On ‘Synthetic Rescue’

 

A new small-molecule approach to turning on beneficial genes to counteract disease-causing mutations is being pioneered by Insmed’s UK-based scientists.

AI-First, Big Pharma, Chinese Firms In Race - What’s Ahead For PRMT5 Inhibitors

 
• By 

As AI-driven firms including Insilico, big pharmas J&J, Amgen, GSK and AstraZeneca and Chinese and Indian firms like BeOne and Dr. Reddy’s advance PRMT5 inhibitor candidates, what’s driving interest, what could lead to the first global approval and what are the challenges ahead?